Evidence map›Paper›PMID 39555932›Full record

ArticleJournal of clinical microbiology2024

A simplified pyrazinamidase test for

Hsin-Hua Chan, Yu-Chen Wang, Ruwen Jou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hsin-Hua ChanTuberculosis Research Center, Centers for Disease Control, Ministry of Health and Welfare, Taipei, Taiwan.ORCID 0009-0009-8582-7827
Yu-Chen WangTuberculosis Research Center, Centers for Disease Control, Ministry of Health and Welfare, Taipei, Taiwan.ORCID 0009-0008-8373-8938
Ruwen JouTuberculosis Research Center, Centers for Disease Control, Ministry of Health and Welfare, Taipei, Taiwan.ORCID 0000-0002-9378-6801

Funding

MOHW | Taiwan Centers for Disease Control (TCDC) MOHW109-CDC-C-315-113402MOHW | Taiwan Centers for Disease Control (TCDC) MOHW110-CDC-C-315-114405MOHW | Taiwan Centers for Disease Control (TCDC) MOHW111-CDC-C- 315-124305MOHW | Taiwan Centers for Disease Control (TCDC) MOHW112-CDC-C-315-134305MOHW | Taiwan Centers for Disease Control (TCDC) MOHW113-CDC-C-315-144308
6 · The paper itself

Abstract

Pyrazinamide (PZA) is an important first-line drug for tuberculosis (TB) treatment by eradicating the persisting IMPORTANCE: We developed and validated a simple pyrazinamidase (PZase) test for pyrazinamide (PZA) antimicrobial susceptibility testing (AST). Our results demonstrated that the PZase test had high agreement with the

Indexed as

AmidohydrolasesAntitubercular AgentsMicrobial Sensitivity TestsMycobacterium tuberculosisPyrazinamideDrug Resistance, BacterialHumansMutationMycobacterium bovisTuberculosisAmidohydrolasesAntitubercular AgentsPncA protein, Mycobacterium tuberculosisPyrazinamidepyrazinamide deamidaseantimicrobial susceptibility testingMycobacterium tuberculosispyrazinamidase testpyrazinamidetuberculosis

Identifiers

PMID39555932
PMCPMC11633146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.